User login
Research and Reviews for the Practicing Oncologist
Update on therapies for lymphoproliferative disorders
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Immunotherapy moves into the breast cancer landscape
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer
Radiation exposure is associated with an increased risk of secondary cancers. Knowing the approximate radiation exposure from diagnostic procedures in the first year after a breast cancer diagnosis could help educate patients and allow physicians to monitor them more closely for potential risks.
Click on the PDF icon at the top of this introduction to read the full article.
Radiation exposure is associated with an increased risk of secondary cancers. Knowing the approximate radiation exposure from diagnostic procedures in the first year after a breast cancer diagnosis could help educate patients and allow physicians to monitor them more closely for potential risks.
Click on the PDF icon at the top of this introduction to read the full article.
Radiation exposure is associated with an increased risk of secondary cancers. Knowing the approximate radiation exposure from diagnostic procedures in the first year after a breast cancer diagnosis could help educate patients and allow physicians to monitor them more closely for potential risks.
Click on the PDF icon at the top of this introduction to read the full article.
Rectal cancer management in elderly patients: experience of a single Portuguese institution
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Dying in America: implications for oncology of the recent IOM report
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
David Henry's JCSO podcast, December 2014
In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.
In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.
In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.
Predictors of resolution in navigated patients with abnormal cancer screening tests
Objective To identify predictors of resolution of abnormal cancer screening tests in patients who received navigation.
Methods We examined data on patients with abnormal breast (n = 256) or cervical (n = 150) screening tests or symptoms who received navigation as part of the Ohio Patient Navigator Research Program during 2007-2010. We used multivariable Cox proportional hazards regression models to identify predictors of time to resolution (ie, when a patient’s clinical abnormality or abnormal screening test was determined to be a benign condition or a cancer diagnosis).
Results The median time to resolution was 183 days for navigated patients with breast abnormalities and 172 days for navigated patients with cervical abnormalities. In patients with breast abnormalities, those who reported at least 1 barrier to care during navigation (HR, 0.66; 95% CI, 0.51-0.86) or higher perceived stress (HR, 0.90; 95% CI, 0.82-0.98) had slower resolution. Among patients with cervical abnormalities, those who reported at least 1 barrier to care during navigation had slower resolution (HR, 0.62; 95% CI, 0.42-0.91). Patients with cervical abnormalities had faster resolution if they had private health insurance, but this effect was present only in younger women (interaction P = .003).
Limitations Unknown generalizability of results because patients were female and from clinics in central Ohio.
Conclusions Several variables predicted whether patient navigation led to faster resolution, and predictors differed somewhat by disease site. Results will be useful in improving current patient navigation programs and designing future programs.
Funding American Cancer Society and the National Institutes of Health
Click on the PDF icon at the top of this introduction to read the full article.
Objective To identify predictors of resolution of abnormal cancer screening tests in patients who received navigation.
Methods We examined data on patients with abnormal breast (n = 256) or cervical (n = 150) screening tests or symptoms who received navigation as part of the Ohio Patient Navigator Research Program during 2007-2010. We used multivariable Cox proportional hazards regression models to identify predictors of time to resolution (ie, when a patient’s clinical abnormality or abnormal screening test was determined to be a benign condition or a cancer diagnosis).
Results The median time to resolution was 183 days for navigated patients with breast abnormalities and 172 days for navigated patients with cervical abnormalities. In patients with breast abnormalities, those who reported at least 1 barrier to care during navigation (HR, 0.66; 95% CI, 0.51-0.86) or higher perceived stress (HR, 0.90; 95% CI, 0.82-0.98) had slower resolution. Among patients with cervical abnormalities, those who reported at least 1 barrier to care during navigation had slower resolution (HR, 0.62; 95% CI, 0.42-0.91). Patients with cervical abnormalities had faster resolution if they had private health insurance, but this effect was present only in younger women (interaction P = .003).
Limitations Unknown generalizability of results because patients were female and from clinics in central Ohio.
Conclusions Several variables predicted whether patient navigation led to faster resolution, and predictors differed somewhat by disease site. Results will be useful in improving current patient navigation programs and designing future programs.
Funding American Cancer Society and the National Institutes of Health
Click on the PDF icon at the top of this introduction to read the full article.
Objective To identify predictors of resolution of abnormal cancer screening tests in patients who received navigation.
Methods We examined data on patients with abnormal breast (n = 256) or cervical (n = 150) screening tests or symptoms who received navigation as part of the Ohio Patient Navigator Research Program during 2007-2010. We used multivariable Cox proportional hazards regression models to identify predictors of time to resolution (ie, when a patient’s clinical abnormality or abnormal screening test was determined to be a benign condition or a cancer diagnosis).
Results The median time to resolution was 183 days for navigated patients with breast abnormalities and 172 days for navigated patients with cervical abnormalities. In patients with breast abnormalities, those who reported at least 1 barrier to care during navigation (HR, 0.66; 95% CI, 0.51-0.86) or higher perceived stress (HR, 0.90; 95% CI, 0.82-0.98) had slower resolution. Among patients with cervical abnormalities, those who reported at least 1 barrier to care during navigation had slower resolution (HR, 0.62; 95% CI, 0.42-0.91). Patients with cervical abnormalities had faster resolution if they had private health insurance, but this effect was present only in younger women (interaction P = .003).
Limitations Unknown generalizability of results because patients were female and from clinics in central Ohio.
Conclusions Several variables predicted whether patient navigation led to faster resolution, and predictors differed somewhat by disease site. Results will be useful in improving current patient navigation programs and designing future programs.
Funding American Cancer Society and the National Institutes of Health
Click on the PDF icon at the top of this introduction to read the full article.